ATE511858T1 - 2,4,6-triamino-1,3,5-triazin-derivat - Google Patents

2,4,6-triamino-1,3,5-triazin-derivat

Info

Publication number
ATE511858T1
ATE511858T1 AT03737464T AT03737464T ATE511858T1 AT E511858 T1 ATE511858 T1 AT E511858T1 AT 03737464 T AT03737464 T AT 03737464T AT 03737464 T AT03737464 T AT 03737464T AT E511858 T1 ATE511858 T1 AT E511858T1
Authority
AT
Austria
Prior art keywords
bec
potassium channel
triamino
action
channel inhibitor
Prior art date
Application number
AT03737464T
Other languages
English (en)
Inventor
Hideki Kubota
Takeshi Suzuki
Masanori Miura
Eiichi Nakai
Kiyoshi Yahiro
Akira Miyake
Shinobu Mochizuki
Kazuhiro Nakato
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE511858T1 publication Critical patent/ATE511858T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/54Three nitrogen atoms
    • C07D251/70Other substituted melamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT03737464T 2002-02-05 2003-02-03 2,4,6-triamino-1,3,5-triazin-derivat ATE511858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002028844 2002-02-05
PCT/JP2003/001065 WO2003066099A1 (fr) 2002-02-05 2003-02-03 Derives de 2,4,6-triamino-1,3,5-triazine

Publications (1)

Publication Number Publication Date
ATE511858T1 true ATE511858T1 (de) 2011-06-15

Family

ID=27677870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737464T ATE511858T1 (de) 2002-02-05 2003-02-03 2,4,6-triamino-1,3,5-triazin-derivat

Country Status (12)

Country Link
US (2) US7375222B2 (de)
EP (1) EP1479397B1 (de)
JP (1) JP4325402B2 (de)
KR (2) KR100875362B1 (de)
CN (3) CN102151273B (de)
AT (1) ATE511858T1 (de)
AU (1) AU2003244463A1 (de)
CA (1) CA2475432C (de)
ES (1) ES2364645T3 (de)
MX (1) MXPA04007590A (de)
PT (1) PT1479397E (de)
WO (1) WO2003066099A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
US7173032B2 (en) * 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
CN102151273B (zh) * 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
WO2005003103A2 (en) * 2003-06-30 2005-01-13 Astrazeneca Ab 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
CN1629157A (zh) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 哌嗪三嗪类化合物、其制备方法及药物组合物
ITMI20050222A1 (it) * 2005-02-15 2006-08-16 Milano Politecnico Lipidi cationici per la trasfezione di acidi nucleici
DK1910384T3 (da) * 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
AU2007209903B2 (en) * 2006-02-01 2012-09-13 Merck Sharp & Dohme Corp. Potassium channel inhibitors
WO2007095812A1 (fr) * 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Composés triazine [1,3,5] substitués, procédés de préparation et utilisations de ceux-ci
JP2009545592A (ja) * 2006-07-31 2009-12-24 プリーシス・ファーマシューティカルズ・インコーポレイテッド コード化小分子ライブラリーからのオーロラキナーゼ阻害剤
ES2699585T3 (es) * 2006-12-15 2019-02-11 Nantbio Inc Derivados de triazina y sus aplicaciones terapéuticas
CA2676920A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperidine derivatives
WO2008131547A1 (en) * 2007-04-30 2008-11-06 Prometic Biosciences Inc. 'triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives'
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TWI389893B (zh) * 2007-07-06 2013-03-21 Astellas Pharma Inc 二(芳胺基)芳基化合物
WO2009015254A1 (en) * 2007-07-25 2009-01-29 Bristol-Myers Squibb Company Triazine kinase inhibitors
CN101868459B (zh) 2007-09-21 2013-12-18 阿雷生物药品公司 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物
WO2009049165A1 (en) * 2007-10-11 2009-04-16 Smithkline Beecham Corporation Novel seh inhibitors and their use
EP2217068A4 (de) * 2007-10-11 2011-09-14 Glaxosmithkline Llc Neue seh-hemmer und ihre verwendung
KR101546111B1 (ko) * 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 신규한 sEH 억제제 및 그의 용도
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
AU2009301210B2 (en) * 2008-10-09 2014-05-15 F. Hoffmann-La Roche Ag Modulators for amyloid beta
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
CA2660962A1 (en) * 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
CA2660954A1 (en) * 2009-03-31 2010-09-30 Astellas Pharma Inc. Novel salt of 1,3,5-triazine-2,4,6-triamine derivative
US20100256152A1 (en) * 2009-04-03 2010-10-07 Astellas Pharma Inc. Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en) * 2009-04-03 2013-03-19 Astellas Pharma Inc. Salt of 1,3,5-triazine-2,4,6-triamine derivative
JPWO2010137689A1 (ja) * 2009-05-29 2012-11-15 アステラス製薬株式会社 注意欠陥/多動性障害新規予防用及び/又は治療用医薬組成物
BRPI1011318A2 (pt) * 2009-06-09 2019-09-24 California Capital Equity Llc derivados de triazina e suas aplicações terapêuticas
EP2488032B1 (de) * 2009-09-23 2016-11-02 Albert Einstein College of Medicine, Inc. Prostaglandintransporterhemmer und ihre verwendung
EP2332926A1 (de) * 2009-11-23 2011-06-15 Borealis Agrolinz Melamine GmbH Auf Melamin basierende Mannich-Verbindungen und Herstellungsverfahren dafür
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
CN102070619B (zh) * 2010-11-29 2013-06-05 河北大学 一种三嗪衍生物及制备方法和其在植物抗菌剂中的应用
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ(アリールアミノ)アリール化合物の製造方法及びその合成中間体
KR101472083B1 (ko) * 2012-10-22 2014-12-16 광주과학기술원 ENOblock을 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물
EP2774922A1 (de) * 2013-03-04 2014-09-10 Borealis Agrolinz Melamine GmbH Verfahren zum Erhalten einer funktionalisierten Triazinverbindung und die mit dem Verfahren erhaltene Triazinverbindung
US9914709B2 (en) * 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
CN105555779B (zh) 2013-07-16 2019-05-10 巴斯夫欧洲公司 除草的嗪类
EP3122736A1 (de) * 2014-03-28 2017-02-01 Basf Se Diaminotriazinderivate als herbizide
CN106458937A (zh) 2014-04-11 2017-02-22 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
BR112016022782B1 (pt) * 2014-04-23 2020-01-28 Basf Se composto de diaminotriazina, composição agroquímica e uso de um composto
EP3134391A1 (de) * 2014-04-23 2017-03-01 Basf Se Diaminotriazinverbindungen und deren verwendung als herbizide
WO2016059647A2 (en) * 2014-10-13 2016-04-21 SHRI CHHATRAPTI SHIVAJI COLLEGE Maharashtra, India) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
CN105294588A (zh) * 2015-11-25 2016-02-03 武汉工程大学 含氟三嗪衍生物及其制备方法和用途
WO2018230595A1 (ja) * 2017-06-14 2018-12-20 富士フイルム株式会社 組成物、膜、レンズ、固体撮像素子、化合物
CN108276351A (zh) * 2018-02-11 2018-07-13 天津大学 具有潜在抗癌效果化合物及其测定方法
KR102022323B1 (ko) * 2018-03-30 2019-09-18 정하윤 트리아진 화합물 및 이의 용도
CN111662242B (zh) * 2019-03-08 2023-10-24 中国药科大学 杂环类idh突变体抑制剂、其制备方法及用途
CN112759557B (zh) * 2019-11-04 2023-12-29 圣奥化学科技有限公司 具有抗老化和耐变色功效的化合物及其制备方法
KR20230040022A (ko) * 2021-09-15 2023-03-22 주식회사 펩토이드 다제 내성균 항균 조성물 및 그의 제조방법
WO2024128802A1 (ko) * 2022-12-15 2024-06-20 부산대학교 산학협력단 간과 신장의 염증 및 섬유화 치료 효과가 있는 신규 트리아진 유도체 및 이의 제조방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB951667A (en) 1961-04-25 1964-03-11 Ici Ltd New water soluble azo dyestuffs containing quaternary ammonium groups
JPS5111861Y2 (de) 1971-06-11 1976-03-31
DE3440777C2 (de) * 1983-11-14 1998-09-03 Clariant Finance Bvi Ltd Neue sulfonsäuregruppenhaltige, basische Azoverbindungen, deren Herstellung und Verwendung als Farbstoffe
JPS61246261A (ja) 1985-04-25 1986-11-01 Toyo Ink Mfg Co Ltd 顔料分散剤
IL87542A (en) * 1987-08-28 1993-01-31 Uniroyal Chem Co Inc Arylenediamino substituted triazine derivatives, processes for the preparation thereof and compositions containing the same
US4794135A (en) * 1987-08-28 1988-12-27 Uniroyal Chemical Company, Inc. Arylenediamine substituted triazines
CH684948A5 (de) * 1992-05-13 1995-02-15 Sandoz Ag Basische sulfogruppenhaltige Disazoverbindungen.
DE4430094A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von 3,5-Dicarbonsäureester-1,4-Dihydropyridinen als Arzneimittel
US6117996A (en) * 1995-09-20 2000-09-12 Novo Nordisk A/S Triazine based ligands and use thereof
WO1997042267A1 (en) * 1996-05-03 1997-11-13 Alliedsignal Inc. Novel nylon compositions
EP0818450B1 (de) * 1996-07-08 2003-01-15 Ciba SC Holding AG Triazinderivate als UV-Filter in Sonnenschutzmitteln
JP3967783B2 (ja) * 1996-07-31 2007-08-29 富士フイルム株式会社 顔料分散組成物及びそれを用いた着色感光性組成物
IT1284525B1 (it) * 1996-09-13 1998-05-21 3V Sigma Spa Derivati di benzossazolo loro uso come stabilizzanti contro le radiazioni uv
WO1999001442A1 (en) * 1997-07-02 1999-01-14 Zeneca Limited Triazine derivatives and their use as antibacterial agents
JPH1143448A (ja) 1997-07-09 1999-02-16 Nippon Soda Co Ltd フェノール系分子化合物を使用する反応方法
DE19735800A1 (de) * 1997-08-18 1999-02-25 Boehringer Ingelheim Pharma Triazine mit adenosinantagonistischer Wirkung
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンa3拮抗剤
JP3518300B2 (ja) 1997-11-17 2004-04-12 東洋インキ製造株式会社 顔料分散剤、及びそれを含有する顔料組成物
US6123763A (en) * 1997-12-22 2000-09-26 Toyo Ink Mfg. Co., Ltd. Pigment dispersing agent and pigment composition containing the same
CA2318362A1 (en) 1998-01-13 1999-07-22 Sharon T. Cload Triazine antiviral compounds
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
EP0945447A1 (de) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
ATE292120T1 (de) * 1998-07-02 2005-04-15 Neurosearch As Kaliumkanal-blockierende mittel
US20020099197A1 (en) * 1998-07-21 2002-07-25 Rory A.J. Curtis Novel potassium channel molecules and uses therefor
JP2002544258A (ja) 1999-05-12 2002-12-24 ニューロサーチ、アクティーゼルスカブ イオンチャネル調節剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
WO2001002406A1 (en) 1999-06-29 2001-01-11 Neurosearch A/S Potassium channel blocking agents
JP4919566B2 (ja) 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
WO2001066743A2 (en) 2000-03-03 2001-09-13 Millennium Pharmaceuticals, Inc. A potassium channel molecule and uses therefor
US6630469B2 (en) * 2000-05-09 2003-10-07 Bristol-Myers Squibb Company 5-HT7 receptor antagonists
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
PL369600A1 (en) 2001-09-21 2005-05-02 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
JP3679403B2 (ja) * 2001-11-14 2005-08-03 アステラス製薬株式会社 トランスジェニック動物
CN102151273B (zh) * 2002-02-05 2015-11-25 安斯泰来制药有限公司 2,4,6-三氨基-1,3,5-三嗪衍生物

Also Published As

Publication number Publication date
CA2475432C (en) 2011-04-05
JP4325402B2 (ja) 2009-09-02
CN1625410A (zh) 2005-06-08
CN102151273B (zh) 2015-11-25
US7375222B2 (en) 2008-05-20
WO2003066099A1 (fr) 2003-08-14
MXPA04007590A (es) 2004-12-06
EP1479397B1 (de) 2011-06-08
PT1479397E (pt) 2011-09-01
AU2003244463A1 (en) 2003-09-02
ES2364645T3 (es) 2011-09-08
CN102151273A (zh) 2011-08-17
KR20040081485A (ko) 2004-09-21
JPWO2003066099A1 (ja) 2005-05-26
US20080227785A1 (en) 2008-09-18
KR20060030922A (ko) 2006-04-11
US20060194803A1 (en) 2006-08-31
EP1479397A1 (de) 2004-11-24
CN1939307A (zh) 2007-04-04
KR100581309B1 (ko) 2006-05-22
KR100875362B1 (ko) 2008-12-22
EP1479397A4 (de) 2009-01-07
CA2475432A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
ATE511858T1 (de) 2,4,6-triamino-1,3,5-triazin-derivat
ATE453393T1 (de) Verwendung von pyridylamiden als angiogenesehemmer
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
GT200300040A (es) Composicion de ziprasidona y controles sinteticos
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
CO5611137A2 (es) Composiciones de clorhidrato de naltrexona
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
CR7332A (es) INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACION
ATE481093T1 (de) Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
DK1404324T4 (da) Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
WO2004080422A3 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
DK1855677T3 (da) 3,11 B-CIS-dihydrotetrabanezin til behandling af skizofreni og andre psykoser
DK0842934T3 (da) 5-HT1F agonister
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
CY1110343T1 (el) 2-(πυριδιν-2-υλο)-πυριμιδινες και η χρησιμοποιηση του για την καταπολεμηση επιζημιων μυκητων
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
BRPI0407512A (pt) derivados de indolilmaleimida
BRPI0409376A (pt) derivados de indeno como agentes farmacêuticos
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
PT1042954E (pt) Composicoes e metodos herbicidas sinergicos compreendendo compostos de dinitroanilina e imidazolinona

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1479397

Country of ref document: EP